In the Loop: Gabe's bell to 'honor the fighting, remember the resting, and party on with the survivors'
Gabe Carranza walked into the lobby on the 16th floor of the Mayo Building. It was a walk he'd made more times than he could count over the past three years and 70 days. But this walk was different. It marked the end of Gabe's treatment for?acute lymphoblastic leukemia. The lobby was filled with family, [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 2, 2019 Category: Databases & Libraries Source Type: news

Five-year-old who won the nation’s heart in his battle against leukaemia has found a stem-cell donor
Oscar Saxelby-Lee, of St John's, Worcester, was diagnosed with the aggressive blood cancer acute lymphoblastic leukaemia on December 28 last year after his parents noticed bruising. (Source: the Mail online | Health)
Source: the Mail online | Health - March 29, 2019 Category: Consumer Health News Source Type: news

HSCT Remains Standard in Childhood ALL, Despite CAR T-Cells HSCT Remains Standard in Childhood ALL, Despite CAR T-Cells
Clinicians should continue to rely on matched donor stem cell transplants to treat childhood acute lymphoblastic leukemia, while more data on novel CAR T-cell therapies is gathered, says German expert.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 26, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Favorable Outcomes Seen in Long Term for ALLR3 Trial
Findings for risk - stratified tx in B - cell precursor acute lymphoblastic leukemia, late bone marrow relapse (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 19, 2019 Category: Cancer & Oncology Tags: Oncology, Pathology, Pediatrics, Journal, Source Type: news

Favorable Outcomes Seen in Long Term for ALLR3 Trial
TUESDAY, March 19, 2019 -- For children with B-cell precursor acute lymphoblastic leukemia with late bone marrow relapse, risk stratification by minimal residual disease seems to be an effective strategy for treatment, according to a study recently... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 19, 2019 Category: Pharmaceuticals Source Type: news

Only About Half of Elderly Newly Diagnosed With ALL Receive Tx
FRIDAY, March 8, 2019 -- Almost half of elderly patients newly diagnosed with acute lymphoblastic leukemia (ALL) do not receive treatment, according to a study recently published in Leukemia& Lymphoma. Christopher Kim, M.P.H., Ph.D., from Amgen... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 8, 2019 Category: Pharmaceuticals Source Type: news

Washington mom says she's cant vaccinate her five-year-old battling cancer and slams anti-vaxxers
Kai Bonneau, five, of Vancouver, Washington, has been battling acute lymphoblastic leukemia. He can't receive any vaccines until he's done with chemotherapy treatments. (Source: the Mail online | Health)
Source: the Mail online | Health - March 5, 2019 Category: Consumer Health News Source Type: news

Genetic Variant Tied to Leukemia Risk in Hispanic Children
Novel susceptibility locus identified in the ERG gene for acute lymphoblastic leukemia (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 25, 2019 Category: Cancer & Oncology Tags: Oncology, Pathology, Pediatrics, Journal, Source Type: news

Genetic Variant Tied to Leukemia Risk in Hispanic Children
MONDAY, Feb. 25, 2019 -- Genetic variations have been identified in the ERG gene that are associated with an increased risk for acute lymphoblastic leukemia (ALL) in Hispanic children, according to a study recently published in Blood. Noting that... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 25, 2019 Category: Pharmaceuticals Source Type: news

Mother claims she took her daughter to the GP FIVE TIMES before she was diagnosed with leukaemia
Sharon Mcalister, 35, of Rutherglen, South Lanarkshire, alleges she took her daughter Kaiann to three separate GPs five times before the youngster was told she had acute lymphoblastic leukaemia. (Source: the Mail online | Health)
Source: the Mail online | Health - February 25, 2019 Category: Consumer Health News Source Type: news

Genetic variations in a fourth gene linked to elevated leukemia risk in Hispanic children
(St. Jude Children's Research Hospital) Progress reported on understanding why Hispanic children are more likely to develop acute lymphoblastic leukemia and to die of the disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 14, 2019 Category: Cancer & Oncology Source Type: news

Obesity Linked to Adverse Events in Children With Leukemia
WEDNESDAY, Feb. 13, 2019 -- For children with acute lymphoblastic leukemia (ALL), obesity is associated with an increased risk for adverse events during premaintenance chemotherapy, according to a study published in the February issue of Pediatric... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 13, 2019 Category: Pharmaceuticals Source Type: news

Allogeneic Transplants No Benefit in Hypodiploid ALL Allogeneic Transplants No Benefit in Hypodiploid ALL
Children with hypodiploid acute lymphoblastic leukemia, a rare form of the disease with a poor prognosis, have no survival benefit from allogeneic transplant and should not undergo it, say US doctors.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 25, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Addition of BMT Not Indicated in Some With Peds Hypodiploid ALL
WEDNESDAY, Jan. 23, 2019 -- For some children with hypodiploid acute lymphoblastic leukemia (ALL), allogeneic hematopoietic cell transplantation does not improve outcomes compared with chemotherapy alone, according to a study published online Jan.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 23, 2019 Category: Pharmaceuticals Source Type: news

European Commission Approves BLINCYTO(R) (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia
BLINCYTO is the First and Only Therapy for Minimal Residual Disease Approved in the European Union Approval Based on Data From the Phase 2 BLAST Study, the Largest Prospective Trial in Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia TH... Biopharmaceuticals, Oncology, Regulatory Amgen, BLINCYTO, blinatumomab, Acute Lymphoblastic Leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 22, 2019 Category: Pharmaceuticals Source Type: news

European Commission Approves BLINCYTO ® (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia
BLINCYTO is the First and Only Therapy for Minimal Residual Disease Approved in the European Union Approval Based on Data From the Phase 2 BLAST Study, the Largest Prospective Trial in Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia THOUSAND OAKS, Calif., Jan. 22, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved an expanded indication for BLINCYTO® (blinatumomab) monotherapy to include adult patients with Philadelphia chromosome negative (Ph-) CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remissi...
Source: Amgen News Release - January 22, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

No substantial benefit from transplantation reported for a high-risk leukemia subtype
(St. Jude Children's Research Hospital) Study led by St. Jude Children's Research Hospital found treatment guided by measuring minimal residual disease was associated with better outcomes for hypodiploid acute lymphoblastic leukemia patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 18, 2019 Category: Cancer & Oncology Source Type: news

Family of a cancer-stricken girl have sparked up a friendship with the 'angel' who saved her life
Skylah Ballentine-Brain, now eight, was diagnosed with acute lymphoblastic leukaemia at less than one-year-old, while her family were living in Cape Town. She was forced to endure chemotherapy. (Source: the Mail online | Health)
Source: the Mail online | Health - January 7, 2019 Category: Consumer Health News Source Type: news

Sprycel (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Sprycel® (dasatinib) tablets to include the treatment of pediatric patients... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 3, 2019 Category: Drugs & Pharmacology Source Type: news

HEALTH NOTES: Ellie Mae stars as Santa after beating cancer  
Ellie Mae Wile-Dunne (pictured), who was diagnosed with the the blood cancer acute lymphoblastic leukaemia when she was four, is starring in cancer charity CLIC Sargent ’s online ad. (Source: the Mail online | Health)
Source: the Mail online | Health - December 22, 2018 Category: Consumer Health News Source Type: news

FDA Approves Two New Drugs for ALL and BPDCN FDA Approves Two New Drugs for ALL and BPDCN
The FDA has granted approval for a drug to be used in acute lymphoblastic leukemia and the first treatment approved for blastic plasmacytoid dendritic cell neoplasm.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 21, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves New Enzyme Product for ALL FDA Approves New Enzyme Product for ALL
The FDA has granted approval for a new enzyme product, calaspargase pegol-mknl, to be used in acute lymphoblastic leukemia.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 21, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Asparlas (calaspargase pegol-mknl) for Acute Lymphoblastic Leukemia (ALL)
On December 20, 2018, the Food and Drug Administration approved calaspargase pegol-mknl (ASPARLAS, Servier Pharmaceuticals LLC), an asparagine specific enzyme, as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 20, 2018 Category: Drugs & Pharmacology Source Type: news

NSU researchers uncover genetic marker, predictor of early relapse in pediatric ALL
(Nova Southeastern University) Researchers recently discovered that by testing the level of NER (nucleotide excision repair) gene expression, pediatric oncologists can determine the likelihood of early relapse (less than three years) in their acute lymphoblastic leukemia (ALL) patients. This (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 13, 2018 Category: Cancer & Oncology Source Type: news

Amgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO ® (Blinatumomab) In Patients With Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
First and Only EU Marketing Authorization Application to Include Presence of Minimal Residual Disease Application Based on Data From the Phase 2 BLAST Study, the Largest Prospective Trial in Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia THOUSAND OAKS, Calif., Nov. 16, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to expand the current indication for BLINCYTO® (blinatumomab) monotherapy to include adult patients with Philadelphia chromosome negative CD19 ...
Source: Amgen News Release - November 16, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present New Data Showcasing Extensive Portfolio And Exciting Early Oncology Pipeline At ASH 2018
First-in-Human Data Evaluating AMG 420 in Multiple Myeloma and AMG 330 in Acute Myeloid Leukemia Underscore Potential of BiTE® Immunotherapy Platform Across Hematologic Malignancies BLINCYTO® (blinatumomab) Long-Term Data Demonstrate Benefits of Achieving Complete MRD Response in Adult Patients With Acute Lymphoblastic Leukemia and Reinforce BiTE® Proof-of-Concept Data From Multiple Myeloma Research Foundation CoMMpass Trial of KYPROLIS® (carfilzomib) in Newly Diagnosed Multiple Myeloma Patients to be Presented at ASH THOUSAND OAKS, Calif., Nov. 1, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today ann...
Source: Amgen News Release - November 1, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Low-fat diet increases cancer survival rate in mice, study finds
Something as simple as a change in diet can potentially help to increase the cancer survival rate of obese children with acute lymphoblastic leukemia, the most common childhood cancer, according to a new study by UCLA scientists.The research team, led by Dr. Steven Mittelman, chief of pediatric endocrinology at  UCLA Mattel Children ’s Hospital and member of the  UCLA Jonsson Comprehensive Cancer Center, administered the chemotherapy drug vincristine to obese and non-obese mice with leukemia. Researchers discovered that if they switched the obese mice from a high-fat to a low-fat diet immediately befor...
Source: UCLA Newsroom: Health Sciences - November 1, 2018 Category: Universities & Medical Training Source Type: news

High hospital costs for acute lymphoblastic leukaemia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2018 Category: Drugs & Pharmacology Source Type: news

Low-fat diet increases cancer survival rate in mice, study finds
(University of California - Los Angeles Health Sciences) Something as simple as a change in diet can potentially help to increase the cancer survival rate of obese children with acute lymphoblastic leukemia, the most common childhood cancer, according to a new study by UCLA scientists. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 31, 2018 Category: Cancer & Oncology Source Type: news

Birth Weight and Risk of Childhood ALL Birth Weight and Risk of Childhood ALL
This study confirms a previously reported association between high birth weight and the risk of developing childhood acute lymphoblastic leukemia. How might this relate to ethnicity and maternal diet?Southern Medical Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 26, 2018 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Journal Article Source Type: news

FDA authorizes first next generation sequencing-based test to detect very low levels of remaining cancer cells in patients with acute lymphoblastic leukemia or multiple myeloma
(Source: Food and Drug Administration)
Source: Food and Drug Administration - September 28, 2018 Category: American Health Source Type: news

BLINCYTO ® (blinatumomab) Approved In Japan For The Treatment Of Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia
First Approved Oncology Treatment From Amgen Astellas Joint Venture BLINCYTO is the First-and-Only Approved CD19-Directed CD3 Bispecific T Cell Engager (BiTE®) Immunotherapy THOUSAND OAKS, Calif., Sept. 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for BLINCYTO® (blinatumomab) for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). BLINCYTO was developed in Japan by Amgen Astellas BioPharma K.K. (AABP), a joint venture between Amgen and Astellas Pharma Inc., a pharmaceuti...
Source: Amgen News Release - September 25, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)
Second Orphan Drug Designation for OBI-3424, a novel first-in-class targeted therapy for solid and liquid tumors that express aldo-keto reductase 1c3 (AKR1C3) enzyme TAIPEI, Taiwan, Sept. 19, 2018 -- (Healthcare Sales & Marketing Network) -- OBI Pharma... Biopharmaceuticals, Oncology, FDA OBI Pharma, Acute Lymphoblastic Leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 19, 2018 Category: Pharmaceuticals Source Type: news

Children who develop ALL may have dysregulated immune function at birth
(American Association for Cancer Research) Neonatal concentrations of eight detectable inflammatory markers were significantly different in children later diagnosed with B-cell precursor acute lymphoblastic leukemia (ALL) compared with controls. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 14, 2018 Category: Cancer & Oncology Source Type: news

Double the Risk for Neurotoxicity for Hispanic Kids From ALL Rx Double the Risk for Neurotoxicity for Hispanic Kids From ALL Rx
Minority children, notably Hispanics, are more susceptible to developing methotrexate-induced neurotoxicity than non-Hispanic children during treatment for acute lymphoblastic leukemia (ALL).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 12, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

St. Jude researchers solve a central mystery of a baffling high-risk leukemia
(St. Jude Children's Research Hospital) St. Jude Children's Research Hospital investigators have unraveled the origins and identified mutations associated with a perplexing form of acute leukemia. The landmark study appears today as an advance online publication in the journal Nature and lays the foundation for more effective treatment of patients with the high-risk cancer.Their treatment is complicated because MPAL does not fit cleanly into a single diagnosis, but includes features of both acute lymphoblastic leukemia and acute myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 12, 2018 Category: Cancer & Oncology Source Type: news

Johns Hopkins All Children's becomes first Florida pediatric hospital to have unique leukemia therapy
Johns Hopkins All Children ’s Hospital is now the first pediatric hospital in Florida offering a cutting-edge cellular immunotherapy for advanced leukemia in children and young adults. It will be offering CAR-T Cell Gene Therapy for leukemia. Chimeric antigen receptor T-cell therapy, or CAR-T, uses a patient’s own cel ls to fight acute lymphoblastic leukemia, which affects more than 3,000 young people in the U.S. each year. This gene therapy is designed for patients who do not respond to standard… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - August 30, 2018 Category: Health Management Authors: Veronica Brezina-Smith Source Type: news

European Commission Approves BLINCYTO ® (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Approval Based on Data From the Phase 1/2 '205 Study THOUSAND OAKS, Calif., Aug. 29, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved an expanded indication for BLINCYTO® (blinatumomab) as monotherapy for the treatment of pediatric patients aged one year or older with Philadelphia chromosome-negative CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL), which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation. The approval is based on ...
Source: Amgen News Release - August 29, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Novartis wins EU approval for CAR-T therapy
Novartis announced that the European Commission has approved Kymriah for the treatment of pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 27, 2018 Category: Pharmaceuticals Source Type: news

Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah ® (tisagenlecleucel)
Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse; and for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. (Source: World Pharma News)
Source: World Pharma News - August 27, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Connectome organization in childhood ALL and risk of delayed neurodevelopment
(Mary Ann Liebert, Inc./Genetic Engineering News) A new study provides novel insights into the cognitive effects of childhood acute lymphoblastic leukemia (ALL) and of chemotherapeutic treatment in long-term survivors of ALL. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 27, 2018 Category: Cancer & Oncology Source Type: news

UCLA Health joins nationwide clinical trial for acute myeloid leukemia
UCLA Health has joined an important national clinical trial that uses genetic testing to match people who have acute myeloid leukemia, or AML, with new therapies. UCLA ’s hospital system is the first in California to offer people the opportunity to participate.The Beat AML Master Trial will evaluate a precision-based medicine approach to treating the disease; it will allow people with the disease to have immediate access to new treatments that are currently in development without having to try more traditional approaches first. The approach could streamline a patient ’s course of treatment and, ultimately, save...
Source: UCLA Newsroom: Health Sciences - August 8, 2018 Category: Universities & Medical Training Source Type: news

Comprehensive pediatric CAR T guidelines developed by MD Anderson and PALISI
(University of Texas M. D. Anderson Cancer Center) Almost one year after the US Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children with acute lymphoblastic leukemia (ALL), researchers at The University of Texas MD Anderson Cancer Center and the Pediatric Acute Lung Injury and Sepsis Investigators Network (PALISI) today published treatment guidelines for managing the treatment in the online issue of Nature Reviews Clinical Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 6, 2018 Category: Cancer & Oncology Source Type: news

Chemotherapy May Alter Brain Activity in Survivors of Childhood ALL Chemotherapy May Alter Brain Activity in Survivors of Childhood ALL
Chemotherapy for childhood acute lymphoblastic leukemia (ALL) is associated with alterations in brain activation during attention and executive-function tasks, researchers report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 29, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO ® (blinatumomab) Label
BLINCYTO is the First-and-Only Approved Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Immunotherapy THOUSAND OAKS, Calif., June 19, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted a full marketing authorization for BLINCYTO® (blinatumomab) based on the overall survival (OS) data from the Phase 3 TOWER study in adult patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). "BLINCYTO is the first single agent immunotherapy to demonstrate superior overall survival benefit ov...
Source: Amgen News Release - June 19, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Novel CD22 CAR-T Works After CD19 Product Failed Novel CD22 CAR-T Works After CD19 Product Failed
A novel CAR T-cell therapy directed against CD22 worked in children with acute lymphoblastic leukemia who had previously progressed after receiving CD19-directed CAR T-cell therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 18, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

' Too Clean' Could Be a Trigger for Childhood Acute Leukemia'Too Clean' Could Be a Trigger for Childhood Acute Leukemia
A lack of microbial exposure among children in industrialized countries may contribute to the development of childhood B-cell acute lymphoblastic leukemia, say researchers.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 25, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Medical News Today: Early exposure to microbes may protect against childhood leukemia
A new analysis suggests that childhood acute lymphoblastic leukemia likely results from genetic predisposition and limited early exposure to germs. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 23, 2018 Category: Consumer Health News Tags: Leukemia Source Type: news

New 'unified theory' of childhood leukemia raises possibility of preventing the disease
Kids who develop acute lymphoblastic leukemia may be the victims of a triple-whammy stroke of bad luck, according to a provocative new theory from a respected British cancer researcher.If the explanation turns out to be correct, it would be good news for the most common type of childhood cancer:... (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - May 23, 2018 Category: Science Authors: Melissa Healy Source Type: news